"Kytopen's Flowfect (R) technology represents an exciting advancement in non-viral cellular engineering, and we're eager to explore how it could complement our donor-to-dose expertise," said Tom ...

Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines Sunflower Therapeutics (Sunflower), a public benefit corporation ...